AVITA Medical Inc ADR

AVH: XASX (AUS)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|>d?!&v!LOCK|lQLOCK|$M@#Y&!

Avita Medical: New Debt Facility Derisks Runway to Positive Cash Flow

Avita's fourth-quarter 2025 sales of USD 18 million were 3% higher than the third quarter, driven by reimbursement support stabilizing. Newly released 2026 guidance implies 15% sales growth at the midpoint. Avita has also secured a new USD 60 million debt facility. Shares rose 9%.

Sponsor Center